About the Company
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CLBS News
Lisata Receives FDA Orphan Drug Designation For LSTA1 To Treat Osteosarcoma
Lisata Therapeutics, Inc. (LSTA) announced on Tuesday that it has received an orphan drug designation from the FDA for LSTA1, the ...
Todd C Girolamo's Net Worth
This is based on reported shares across multiple companies, which include Longeveron Inc., Caladrius Biosciences, Inc., and PROKIDNEY CORP.. Attention insiders: Dive deeper into market movements ...
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Call Transcript
Lisata Therapeutics, Inc. (NASDAQ:LSTA ... with the merger of Cend Therapeutics and our predecessor company, Caladrius Biosciences, forming Lisata Therapeutics, operating expenses decreased ...
Lisata's LSTA1 Gets Rare Pediatric Disease Designation From FDA For Osteosarcoma
(RTTNews) - Lisata Therapeutics, Inc. (LSTA) announced on Thursday ... Track designation from the FDA for pancreatic cancer. Caladrius Biosciences NewsMORE Related Stocks Indices Commodities ...
Aura Biosciences Inc AURA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Assembly Biosciences Inc ASMB
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Evofem Biosciences, Inc. (EVFM)
Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that it has successfully renegotiated the rebate for Phexxi® (lactic acid, citric acid and ...
CTKB Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and ...
Avidity Biosciences Inc
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design ...
Pacira BioSciences Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Forte Biosciences Inc.
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...
Avidity Biosciences Inc (RNA)
In a recent transaction, Michael F. MacLean, the Chief Financial Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), sold 40,000 shares of the company's common stock. The sale, ...
Loading the latest forecasts...